The specter of generic rivalry has repeatedly loomed around copyright’s iconic drug, Sildenafil, raising questions about the future of related drug investments. While first years saw substantial profits, the exclusivity lapse has opened the way for discounted copies, potentially reducing earnings and creating a real danger for investors looking f